HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$57.12
0.11 (0.19%)
▲
5d:
+5.06%
30d:
-7.8%
90d:
-0.9%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$87.12
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$54.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $57.12, which is considered fair relative to its 30-day fair value range of $55.65 to $61.05. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.8) compared to its historical average (12.6). Remarkably, the market is currently pricing in an annual earnings decline of 4.9% over the next few years. This pessimistic expectation contrasts with the company's recent 28.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HAE is in a strong downtrend. Immediate support is located at $51.00, while resistance sits at $60.72.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $80.20 (+40.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HAE is in a strong downtrend. Immediate support is located at $51.00, while resistance sits at $60.72.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $80.20 (+40.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$55.65 -
$61.05
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.4% below Wall St target ($80.20)
Trading Range Analysis
30-Day Trading Range
$55.65 -
$61.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$51.00
Resistance Level
$60.72
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.79
Wall Street Target
$80.20
(+40.4%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
28.4%
Profit Margin
7.3%
Valuation Discount vs History
-4.9% cheaper
PE vs Historical
10.8 vs 12.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.9%
(market-implied from PE analysis)
1-Year Target
$54.32
(-5%)
2-Year Target
$51.66
(-10%)
3-Year Target
$49.13
(-14%)
3-Yr Target (if PE normalizes)
(PE: 11→13)
$57.34
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 7.0%)
$143.04
(+150%)
Base:
(SPY PE: 10.8, Growth: 7.0%)
$70.06
(+23%)
Bear:
(PE: 9.2, Growth: 7.0%)
$59.55
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 15.71 | Current EPS (TTM): $3.63
Bull Case
$91.41
(+60%)
Analyst growth 45.8%, PE expands to 17.3
Base Case
$83.10
(+46%)
Market implied 45.8%, PE stable at 15.7
Bear Case
$38.77
(-32%)
Severe decline -20.0%, PE contracts to 13.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.8 to 12.6
Stabilization Target:
$66.67
(+16.7%)
PE Expansion Potential:
+16.7%
Share & Embed Analysis
Last updated: May 15, 2026 6:27 AM ET
Data refreshes hourly during market hours. Next update: 7:27 AM
Data refreshes hourly during market hours. Next update: 7:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$392 | 62 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 62 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 58 HOLD |
